Helfie AI, a global leader in mobile health technology, has strengthened its Board of Directors with the addition of two healthcare veterans. Antonin (Tony) de Fougerolles, PhD, a distinguished scientist known for his role as founding Chief Scientific Officer at Moderna, joins as Non-Executive Chairman, while Cheryl Buxton, an experienced global healthcare executive, will serve as an Independent Non-Executive Board Member.
Helfie AI’s innovative mobile platform, powered by artificial intelligence, allows smartphone users worldwide to conduct quick and accurate health checks for various conditions. The appointments of de Fougerolles and Buxton mark a key milestone in the company’s mission to transform global healthcare accessibility and engagement.
Commenting on the new appointments, George Tomeski, Helfie AI’s Co-Founder and CEO, said: “Bringing Tony and Cheryl on board is a crucial step forward for Helfie AI. Their extensive experience in healthcare and start-up growth will help us achieve our goal of putting essential, life-saving health checks in the hands of billions globally. As we advance towards commercializing our cutting-edge technology, we are thrilled to have their expertise in scaling companies and navigating the healthcare landscape.”
Dr. de Fougerolles has an impressive 25-year career in drug development, having contributed to the creation of three transformative drug platforms and numerous approved treatments in fields such as infectious diseases, cardiology, and rare conditions. His leadership experience includes scaling start-ups into multi-billion-dollar enterprises, most recently as CEO of Evox Therapeutics. He will advise Helfie AI on company growth, fundraising, and optimizing the platform for various health conditions.
Cheryl Buxton brings a wealth of knowledge from her previous role as Vice Chairman, Pharmaceuticals and R&D at Korn Ferry International, where she helped build high-performing teams across diverse sectors and geographies. Her expertise in global healthcare and organizational development will support Helfie AI’s expansion into a multinational entity, facilitating connections with industry leaders and driving growth.
Dr. de Fougerolles expressed his enthusiasm for joining Helfie AI, stating, “This platform has the potential to transform healthcare by making health checks accessible to everyone, similar to how Apple reshaped the music industry. Early detection of health issues can significantly improve patient outcomes, and I’m excited to collaborate with the team on this groundbreaking technology.”
Ms. Buxton shared her excitement as well, saying, “Helfie AI can bridge the gap in healthcare access for people of different socio-economic backgrounds and regions. Whether it’s a single parent in a rural area or a busy executive in a city, Helfie’s technology enables access to essential health checks. The opportunity to promote a truly equitable approach to preventive healthcare is a driving force behind my decision to join the board.”
Helfie AI uses advanced artificial intelligence to analyze images, videos, audio recordings, or facial scans to identify potential health concerns, providing users with instant results and guidance on next steps. Users retain ownership and control over their health data throughout the process.
About Helfie AI
Founded in Melbourne, Australia, in 2021, Helfie AI has rapidly expanded across Europe, North America, Africa, and Asia, forming B2B partnerships with leading companies. The platform addresses two core challenges in healthcare: increasing participation in preventive care and maximizing the utilization of health data. By making preventive health accessible to all, Helfie AI aims to reduce the $7 trillion spent annually on treating preventable conditions.
Helfie AI offers clear next steps for users, links them to medical care when needed, and supports a variety of health areas, from cardiovascular and skin health to more specialized conditions, enabling users to share AI findings with their healthcare providers.
